Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: Studies of novel centrally acting drugs in healthy volunteers are traditionally concerned with kinetics and tolerability, but useful information may also be obtained from biomarkers of clinical endpoints. This paper provides a systematic overview of CNS‐tests used with SSRIs in healthy subjects. A useful biomarker should meet the following requirements: a consistent response across studies and drugs; a clear response of the biomarker to a therapeutic dose; a dose–response relationship; a plausible relationship between biomarker, pharmacology and pathogenesis. Methods: These criteria were applied to all individual tests found in studies of selective serotonin reuptake inhibitors (SSRIs), performed in healthy subjects since 1966, identified with a systematic MedLine search. Separate databases were created to evaluate the effects of single or multiple dose SSRI‐studies, and for amitriptyline whenever the original report included this antidepressant as a positive control. Doses of the antidepressant were divided into high‐ and low‐dose ranges, relative to a medium range of therapeutic doses. For each test, the drug effects were scored as statistically significant impairment/decrease (–), improvement/increase (+) or no change (=) relative to placebo. Results: 56 single dose studies and 22 multiple dose studies were identified, investigating the effects of 13 different SSRIs on 171 variants of neuropsychological tests, which could be clustered into seven neuropsychological domains. Low single doses of SSRIs generally stimulated tests of attention and memory. High doses tended to impair visual/auditory and visuomotor systems and subjective performance, while showing an acceleration in motor function. The most pronounced effects were observed using tests that measure flicker discrimination (improvement at low doses: 75%, medium doses: 40%, high doses: 43% of studies); REM sleep (inconsistent decrease after medium doses, decrease in 83% of studies after high doses); and EEG recordings, predominantly in alpha (decrease in 60% and 43% of studies after low and medium doses, respectively) and in theta activity (increase in 43% and 33% of studies after medium and high doses, respectively). Amitriptyline generally impaired central nervous system (CNS) functions, which increased with doses. Multiple doses caused less pronounced effects on the reported tests. The most responsive tests to amitriptyline appeared to be EEG alpha and theta, and REM sleep duration. Conclusions: SSRIs in healthy subjects appear to cause slight stimulating effects after low doses, which tend to diminish with dose. The most consistent effects were observed with flicker discrimination tests, EEG (alpha and beta bands), REM sleep duration, and subjective effects at higher doses. These effects are small compared with amitriptyline and other CNS‐active drugs. Multiple dosing with SSRIs caused even fewer measurable differences from placebo, probably due to adaptive processes. SSRI‐effects are best detected with a test battery that is sensitive to general CNS‐stimulation, but such tests only comprise a very small portion of the close to 200 different methods that were found in current review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial
Sharpley, A. L., Williamson, D. J., Attenburrow, M. E. J., Pearson, G., Sargent, P., & Cowen, P. J. (1996) · Psychopharmacology · doi:10.1007/bf02246410 · Cited by 122
Ramaekers, J., Muntjewerff, N., & O'Hanlon, J. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb04468.x · Cited by 103
Robbe, H. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(94)00130-4 · Cited by 91
Saletu, B., Gr�nberger, J., & Linzmayer, L. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243351 · Cited by 78
Nathan, P. J., Sitaram, G., Stough, C., Silberstein, R. B., & Sali, A. (2000) · Behavioral Pharmacology · doi:10.1097/00008877-200011000-00011 · Cited by 43
Wilson, S. J., Bailey, J. E., Alford, C., Weinstein, A., & Nutt, D. J. (2002) · Journal of Psychopharmacology · doi:10.1177/026988110201600406 · Cited by 30
Cited by
Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review
Repantis, D., Schlattmann, P., Laisney, O., & Heuser, I. (2010) · Pharmacological Research · doi:10.1016/j.phrs.2010.04.002 · Cited by 576
Novel melatonin-based therapies: potential advances in the treatment of major depression
Hickie, I. B., & Rogers, N. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60095-0 · Cited by 334
Biomarkers and surrogate endpoints
Aronson, J. K. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02435.x · Cited by 312
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181
A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers
Dumont, G. J. H., & Verkes, R. J. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106063271 · Cited by 149
Self-citation
Metadata
- Authors
- Dumont, G. J. H., De Visser, S. J., Cohen, A. F., & Van Gerven, J. M. A.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2005-04-19
- Volume
- 59
- Issue
- 5
- Pages
- 495-510
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W2007709610
- Cited by
- 107
- References
- 7
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. https://app.cochat.ai/papers/10.1111/j.1365-2125.2005.02342.x
- The paper
- Dumont, G. J. H., De Visser, S. J., Cohen, A. F., & Van Gerven, J. M. A. (2005). Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2005.02342.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.